These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 8895198

  • 1. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R.
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N, Lam YM, Pym J, Campling BG.
    Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677
    [Abstract] [Full Text] [Related]

  • 3. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE, Evans CD, Almquist KC, Slovak ML, Cole SP.
    Cancer Res; 1993 Oct 15; 53(20):4866-73. PubMed ID: 8104687
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM.
    Cancer Res; 1991 Oct 01; 51(19):5275-83. PubMed ID: 1717144
    [Abstract] [Full Text] [Related]

  • 5. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH.
    Cancer Res; 1994 Jan 01; 54(1):152-8. PubMed ID: 7903202
    [Abstract] [Full Text] [Related]

  • 6. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y, Takano H, Nagao S, Fojo T.
    Jpn J Cancer Res; 2001 Sep 01; 92(9):968-74. PubMed ID: 11572765
    [Abstract] [Full Text] [Related]

  • 7. Combined modalities of resistance in etoposide-resistant human KB cell lines.
    Ferguson PJ, Fisher MH, Stephenson J, Li DH, Zhou BS, Cheng YC.
    Cancer Res; 1988 Nov 01; 48(21):5956-64. PubMed ID: 2844393
    [Abstract] [Full Text] [Related]

  • 8. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW, Mirski SE, Cole SP, Sullivan DM.
    Cancer Res; 1994 Feb 01; 54(3):756-62. PubMed ID: 8306338
    [Abstract] [Full Text] [Related]

  • 9. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, Sehested M.
    Cancer Res; 1999 Jul 15; 59(14):3442-50. PubMed ID: 10416608
    [Abstract] [Full Text] [Related]

  • 10. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.
    Cancer Res; 1998 Apr 01; 58(7):1460-8. PubMed ID: 9537249
    [Abstract] [Full Text] [Related]

  • 11. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K, Nakamura T, Ono M, Kusano T, Okada K, Kikuchi A, Adachi N, Kohno K, Higashi K, Kuwano M.
    Oncol Res; 1996 Apr 01; 8(5):197-206. PubMed ID: 8884812
    [Abstract] [Full Text] [Related]

  • 12. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S, Kooistra AJ, de Vries EG, Mulder NH, Zijlstra JG.
    Cancer Res; 1993 Mar 01; 53(5):1064-71. PubMed ID: 8382551
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S, Benchokroun Y, Larsen AK.
    Mol Pharmacol; 1995 May 01; 47(5):898-906. PubMed ID: 7746278
    [Abstract] [Full Text] [Related]

  • 16. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
    Hong JH.
    Hiroshima J Med Sci; 1989 Dec 01; 38(4):197-207. PubMed ID: 2561562
    [Abstract] [Full Text] [Related]

  • 17. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES.
    Oncol Res; 1996 Dec 01; 8(3):101-10. PubMed ID: 8823806
    [Abstract] [Full Text] [Related]

  • 18. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA, Padmanabhan R, Hwang J, Gottesman MM, Pastan I.
    J Cell Physiol; 1993 May 01; 155(2):414-25. PubMed ID: 8097746
    [Abstract] [Full Text] [Related]

  • 19. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
    Yu Q, Mirski SE, Sparks KE, Cole SP.
    Biochemistry; 1997 May 13; 36(19):5868-77. PubMed ID: 9153428
    [Abstract] [Full Text] [Related]

  • 20. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
    Takigawa N, Ohnoshi T, Ueoka H, Yonei T, Kiura K, Tabata M, Kodani T, Kamei H, Segawa Y, Shibayama T.
    Gan To Kagaku Ryoho; 1993 May 13; 20(7):929-35. PubMed ID: 8387762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.